ନିମୋଡିପାଇନ

ନିମୋଡିପାଇନ
Clinical data
Trade names	Nimotop, Nymalize, others
AHFS/Drugs.com	monograph
MedlinePlus	a689010
data	US DailyMed: Nimodipine;
Pregnancy; category	AU: C ; US: C (Risk not ruled out) ; ;
Routes of; administration	Intravenous, by mouth
Legal status
Legal status	US: ℞-only ;
Pharmacokinetic data
Bioavailability	13% (by mouth)
Protein binding	95%
Metabolism	Liver
Onset of action	Rapid
Elimination half-life	8–9 hours
Duration of action	4 hrs
Excretion	Feces and Urine
Identifiers
	IUPAC name 3-(2-Methoxyethyl) 5-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate;
ECHA InfoCard	100.060.096
Chemical and physical data
Formula	C21H26N2O7
Molar mass	୪୧୮.୪୫ g·mol−1
3D model (JSmol)	Interactive image;
Melting point	7 °C (45 °F)
	SMILES O=C(OC(C)C)\C1=C(\N/C(=C(/C(=O)OCCOC)C1c2cccc([N+]([O-])=O)c2)C)C;
	InChI InChI=1S/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3 ; Key:UIAGMCDKSXEBJQ-UHFFFAOYSA-N ;
(verify)

ନିମୋଡିପାଇନ, ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ଏକ ବେପାର ନାମ ନିମୋଟପ, ହେଉଛି, ଏକ ଔଷଧ ଯାହା ସବଆରାକନଏଡ ରକ୍ତସ୍ରାବ ଜନିତ ଭାସୋସ୍ପାଜ୍ମ ରୋକିବା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ । ^[୩] ଏହା ପାଟିରେ କିମ୍ବା ଶିରାରେ ଇଞ୍ଜେକ୍ସନଦ୍ୱାରା ଦିଆଯାଏ ।^[୩] ^[୪] ଏହାର ପ୍ରଭାବ ତୁରନ୍ତ ଆରମ୍ଭ ହୋଇ ପ୍ରାୟ ୪ଘଣ୍ଟା ପର୍ଯ୍ୟନ୍ତ କାର୍ଯ୍ୟକାରୀ ହୁଏ ।^[୨]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ନିମ୍ନ ରକ୍ତଚାପ ଏବଂ ମୁଣ୍ଡବିନ୍ଧା ହୋଇପାରେ ।^[୩] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ମନ୍ଥର ହୃଦସ୍ପନ୍ଦନ, ଇଲିଅସ ବା ମନ୍ଥର ଅନ୍ତନଳୀ ଗତି ହୁଏ ଏବଂ ଥ୍ରମ୍ବୋସାଇଟୋପେନିଆ ବା କମ୍ ପ୍ଲାଲେଟ୍ ହୋଇପାରେ | ^[୪] ଗର୍ଭାବସ୍ଥାରେ ସୁରକ୍ଷା ଅସ୍ପଷ୍ଟ ଅଟେ। ^[୫] ଏହା ଡିହାଇଡ୍ରୋପାଇରିଡାଇନ୍ ଶ୍ରେଣୀର ଏକ କ୍ୟାଲସିୟମ୍ ଚ୍ୟାନେଲ୍ ବ୍ଲକର୍ ।^[୩]

ନିମୋଡିପାଇନ୍ ୧୯୭୧ ମସିହାରେ ପ୍ୟାଟେଣ୍ଟ କରାଯାଇଥିଲା ଏବଂ ୧୯୮୫ରେ ଜର୍ମାନୀରେ ଚିକିତ୍ସା କ୍ଷେତ୍ରରେ ବ୍ୟବହାର ପାଇଁ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୬] ^[୭] ୧୯୮୮ରେ ଏହା ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୩] ଯୁକ୍ତରାଜ୍ୟରେ ୩୦ ମିଗ୍ରା ବିଶିଷ୍ଟ ୧୦୦ଟି ବଟିକାର ମୂଲ୍ୟ ପ୍ରାୟ ୪୦ ପାଉଣ୍ଡ ଥିଲା ।^[୪] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ରାଶିର ମୂଲ୍ୟ ପ୍ରାୟ ୧୭୦ ଡଲାର ଥିଲା ।^[୮]

ଆଧାର

↑ ^୧.୦ ^୧.୧ "Nimodipine Use During Pregnancy". Drugs.com. 15 March 2019. Archived from the original on September 21, 2021. Retrieved 11 April 2020.
↑ ^୨.୦ ^୨.୧ ^୨.୨ Frishman, William H.; Cheng-Lai, Angela; Chen, Julie (29 June 2013). Current Cardiovascular Drugs (in ଇଂରାଜୀ). Springer Science & Business Media. p. 161. ISBN 978-1-4615-6767-7. Archived from the original on November 13, 2021. Retrieved November 13, 2021.
↑ ^୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ "Nimodipine Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on September 21, 2021. Retrieved 13 November 2021.
↑ ^୪.୦ ^୪.୧ ^୪.୨ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 124. ISBN 978-0857114105.
↑ "Nimodipine Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Archived from the original on September 21, 2021. Retrieved 13 November 2021.
↑ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 464. ISBN 9783527607495. Archived from the original on August 29, 2021. Retrieved October 15, 2021.
↑ Bayer AG of Germany (1971-04-10). "New molecular entity with antihypertensive properties" (Patent (Post-Approval)). UK Patent Office / EspaceNet Patent Search. British patent 1,358,951: Patent Office of the United Kingdom. p. GB1358951. Archived from the original on November 12, 2020. Retrieved 11 April 2019. Priority date: 1971-04-10 (...) Date issued: 1974-07-03{{cite web}}: CS1 maint: location (link)
↑ "Nimodipine Prices and Nimodipine Coupons - GoodRx". GoodRx. Retrieved 13 November 2021.

[Drugs.com_pregnancy-1] ୧.୦ ^୧.୧ "Nimodipine Use During Pregnancy". Drugs.com. 15 March 2019. Archived from the original on September 21, 2021. Retrieved 11 April 2020.

[Fris2013-2] ୨.୦ ^୨.୧ ^୨.୨ Frishman, William H.; Cheng-Lai, Angela; Chen, Julie (29 June 2013). Current Cardiovascular Drugs (in ଇଂରାଜୀ). Springer Science & Business Media. p. 161. ISBN 978-1-4615-6767-7. Archived from the original on November 13, 2021. Retrieved November 13, 2021.

[AHFS2021-3] ୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ "Nimodipine Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on September 21, 2021. Retrieved 13 November 2021.

[BNF81-4] ୪.୦ ^୪.୧ ^୪.୨ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 124. ISBN 978-0857114105.

[5] "Nimodipine Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Archived from the original on September 21, 2021. Retrieved 13 November 2021.

[Fis2006-6] Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 464. ISBN 9783527607495. Archived from the original on August 29, 2021. Retrieved October 15, 2021.

[Patent1971-7] Bayer AG of Germany (1971-04-10). "New molecular entity with antihypertensive properties" (Patent (Post-Approval)). UK Patent Office / EspaceNet Patent Search. British patent 1,358,951: Patent Office of the United Kingdom. p. GB1358951. Archived from the original on November 12, 2020. Retrieved 11 April 2019. Priority date: 1971-04-10 (...) Date issued: 1974-07-03{{cite web}}: CS1 maint: location (link)

[8] "Nimodipine Prices and Nimodipine Coupons - GoodRx". GoodRx. Retrieved 13 November 2021.

[୩]

[୪]

[୨]

[୧]

[୫]

[୬]

[୭]

[୮]